Aptose Biosciences Inc. has filed an 8-K report with the SEC on March 23, 2026, detailing an amendment to the employment agreement of Dr. William Rice, the company's Chairman, President, and CEO. The amendment, effective March 12, 2026, clarifies that no deferred compensation plan was established for Dr. Rice, and he is solely responsible for any taxes related to benefits under the original agreement. This filing does not indicate any significant changes to the company's operational or financial outlook, and it appears to be a routine administrative update regarding executive compensation. The amendment is filed as Exhibit 10.1 and is incorporated by reference in the report. The company continues to operate under its existing strategic framework without any immediate changes to its governance or operational execution. The filing is expected to have a neutral impact on the stock price, as it does not introduce any new material information that would significantly affect investor sentiment or the company's market position.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.